drugset / Trial / NCT05238597

A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease

NCT05238597 ↗

Phase 2 Completed 207 enrolled Aramis Biosciences, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The objectives of this trial are to assess the safety, tolerability and efficacy of A197 ophthalmic solution in comparison to a vehicle control in the treatment of subjects with Dry Eye Disease.

Timeline

Start
2022-01-25
Primary completion
2023-01-24
Completion
2023-01-24

Drugs

EvaluationDrugModalityDoseRoute
Subject A197 Unknown — —

Indications